Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions-Reference-Cited by-同舟云学术

Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions

Published:2019-07 Issue: Volume:139 Page:83-86
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Iacovelli Roberto^ORCID,Ciccarese Chiara,Schinzari Giovanni,Maiorano Brigida Anna,Rossi Ernesto,Pierconti Francesco,Bassi Pier Francesco,Bria Emilio^ORCID,Tortora Giampaolo

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference20 articles.

1. The molecular taxonomy of primary prostate cancer;Cancer Genome Atlas Research Network;Cell,2015

2. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study;Culp;Eur. Urol.,2014

3. LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N. Engl. J. Med.,2017

4. Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): detailed safety analyses from the LATITUDE phase 3 trial;Fizazi;J. Clin. Oncol.,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Alpha Therapy in Metastatic Castration Resistance Prostate Cancer;Nuclear Medicine Seminars;2023-09-01

2. UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer;Canadian Urological Association Journal;2022-09-26

3. Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis;Frontiers in Oncology;2022-02-03

4. Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype;Critical Reviews in Oncology/Hematology;2021-07

5. First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings;Critical Reviews in Oncology/Hematology;2021-01